GHK-Cu

GHK-Cu Capsules is supplied as a catalogued research material in capsules, 5mg per capsule, 60 capsules. The 5mg designation is a catalogue concentration, not an established dose. This presentation identifies the listed format and strength; it does not establish the composition or analytical characteristics of an individual batch.

GHK-Cu denotes a copper complex of the tripeptide glycyl-L-histidyl-L-lysine, also described as Copper Tripeptide-1. The name does not uniquely define peptide:copper stoichiometry, counter-ion or solid form. Public records describe materially different complexes, so a molecular formula, molecular mass or registry identifier should not be assigned to these capsules without matching batch documentation.

Chemical properties and registry information

Registry assignments depend on the defined molecular entity and material form. Family-level identifiers are not substitutes for batch-specific identity evidence.

Research background and published evidence

Published research

Published literature examines copper binding and coordination involving the Gly-His-Lys tripeptide. These studies provide a background for investigating peptide–metal interactions and developing analytical methods for defined complexes. Research involving separately manufactured topical and preclinical materials also exists, but those materials are not interchangeable with this capsule presentation.

The relevant evidence must be interpreted against the material actually studied, including its peptide:copper ratio, counter-ion, formulation and experimental conditions. A shared compound name alone does not demonstrate that a published preparation matches the catalogue product.

Current scientific understanding

The chemical identity of a GHK-Cu material requires more than confirmation of the peptide sequence. Total copper, free copper and the Cu:GHK molar ratio are distinct attributes that require appropriate analytical evidence. Findings concerning a defined reference complex cannot establish these attributes for an uncharacterised batch or a finished capsule matrix.

Formulation note

Published research mostly used other materials or routes rather than this capsule formulation. Findings from injected or differently formulated material cannot be transferred to these capsules. The capsule shell and excipient matrix introduce additional compositional variables, and the catalogue strength does not establish equivalence to any published experimental preparation.

Assessment of this presentation therefore requires formulation-specific documentation. Evidence for an isolated peptide–copper complex should be distinguished from evidence obtained on the finished capsules, including how the declared content is defined and measured.

Quality and testing

Quality information must be linked to the exact product and lot through a batch-specific Certificate of Analysis (CoA). A report for another presentation, pack size or similarly named material is not evidence for these capsules. Consult the matching Safety Data Sheet (SDS) for the documented composition and material-specific information.

Relevant documentation should distinguish peptide identity and content, total copper, Cu:GHK ratio, free copper, counter-ion, excipients and relevant elemental impurities. Chromatographic area purity is not equivalent to net analyte content or capsule content uniformity. Only measurements supported by a visible, matching batch report should be treated as available; unreported attributes remain unverified.

Supplied exclusively for laboratory research by qualified professionals. Research use only; not for human or veterinary use. No dosing directions are provided.